Key result
Telemedicine-based oral anticoagulation management yielded a non-significant reduction in thromboembolic events (RR 0.75; 95% CI 0.53-1.07) and similar major bleeding compared to usual care.
Why the study?
Oral anticoagulation management is often challenging, prompting various telemedicine strategies, but evidence comparing their impact against usual care on thromboembolic and bleeding events needed systematic review.
Does telemedicine-based oral anticoagulation management reduce thromboembolic and bleeding events in patients on oral anticoagulation therapy?
Meta-Analysis (n=25,746)
Does telemedicine-based oral anticoagulation management reduce thromboembolic and bleeding events in patients on oral anticoagulation therapy?
Relative Risk: 0.75 (95% CI 0.53–1.07)
Telemedicine-based management of oral anticoagulation improves time in therapeutic range and maintains similar safety and efficacy profiles compared to standard care, supporting its use for remote or integrated care.
Supports telemedicine anticoagulation management for remote care; extends meta-analytic evidence confirming similar safety and efficacy.
Background Oral anticoagulation is the cornerstone treatment of several diseases. Its management is often challenging, and different telemedicine strategies have been implemented to support it. Objective The aim of the study is to systematically review the evidence on the impact of telemedicine-based oral anticoagulation management compared to usual care on thromboembolic and bleeding events. Methods Randomized controlled trials were searched in 5 databases from inception to September 2021. Two independent reviewers performed study selection and data extraction. Total thromboembolic events, major bleeding, mortality, and time in therapeutic range were assessed. Results were pooled using random effect models. Results In total, 25 randomized controlled trials were included (n=25,746 patients) and classified as moderate to high risk of bias by the Cochrane tool. Telemedicine resulted in lower rates of thromboembolic events, though not statistically significant (n=13 studies, relative risk [RR] 0.75, 95% CI 0.53-1.07; I2=42%), comparable rates of major bleeding (n=11 studies, RR 0.94, 95% CI 0.82-1.07; I2=0%) and mortality (n=12 studies, RR 0.96, 95% CI 0.78-1.20; I2=11%), and an improved time in therapeutic range (n=16 studies, mean difference 3.38, 95% CI 1.12-5.65; I2=90%). In the subgroup of the multitasking intervention, telemedicine resulted in an important reduction of thromboembolic events (RR 0.20, 95% CI 0.08-0.48). Conclusions Telemedicine-based oral anticoagulation management resulted in similar rates of major bleeding and mortality, a trend for fewer thromboembolic events, and better anticoagulation quality compared to standard care. Given the potential benefits of telemedicine-based care, such as greater access to remote populations or people with ambulatory restrictions, these findings may encourage further implementation of eHealth strategies for anticoagulation management, particularly as part of multifaceted interventions for integrated care of chronic diseases. Meanwhile, researchers should develop higher-quality evidence focusing on hard clinical outcomes, cost-effectiveness, and quality of life. Trial Registration PROSPERO International Prospective Register of Systematic Reviews CRD42020159208; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=159208
No takes yet. Share an insight, caveat, or question.
Ferreira et al. (2023) conducted a meta-analysis in Diseases requiring oral anticoagulation (n=25,746). Telemedicine-based oral anticoagulation management vs. Usual care was evaluated on Thromboembolic events (RR 0.75, 95% CI 0.53-1.07). Telemedicine-based oral anticoagulation management yielded a non-significant reduction in thromboembolic events (RR 0.75; 95% CI 0.53-1.07) and similar major bleeding compared to usual care.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: